Bharat Biotech completes clinical development for phase III trials and booster doses for BBV154 intranasal Covid vaccine
Bharat Biotech International Limited (BBIL) said today its intranasal Covid-19 vaccine BBV154 has demonstrated to be safe, well-tolerated, and immunogenic […]



